21st Austria weekly - Marinomed Vienna Insurance Group 21/11/2023 [pic1]Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters 2023 Q1-Q3 2022: 7.1 million due to continued demand for Carragelose virus blockers. The increase personnel costs higher R&D expenses and lower research subsidies were reflected operating result -4.4 -3.8 million. period amounted -5.6 million compared -5.8 prior-year period. For platform took necessary steps create an all-year product portfolio a expansion therapeutic area immunology with allergy blocker eye drops. market launches are already preparation 2024. Procter & Gamble also secured rights Carragelose-based spray USA. has paved way further important partnerships candidates Budesolv Tacrosolv which based on Marinosolv
EQS-News: Marinomed Biotech AG / Key word(s): Quarter ResultsMarinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development 21.11.2023 / 07:45 CET/CESTThe issuer is solely responsible for the content of this announcement.Marinomed Biotech AG: Stable revenues in.
Moderna: Calculated Risk Worth Taking For Patient Investors (NASDAQ:MRNA) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.